Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center talked about recognizing the struggles of patients with migraine disorders and the importance of bringing awareness of available treatments to this patient population. [WATCH TIME: 5 minutes]

The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]

The director of the MedStar Georgetown Headache Center talked about an intravenous migraine treatment that could offer long-term relief for most patients who respond well to the initial dose. [WATCH TIME: 5 minutes]

The director of the MedStar Georgetown Headache Center discussed the importance of a healthy clinician-patient relationship and the conversations needed during treatment selection for migraine. [WATCH TIME: 4 minutes]

The director of the MedStar Georgetown Headache Center provided insight on the excitement behind PACAP, how it may offer an alternate way of treating migraine, and where research behind it currently stands. [WATCH TIME: 4 minutes]

The director of the MedStar Georgetown University Hospital Headache Center tells her experience in a medical crossfire as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]

The director of the MedStar Georgetown University Hospital Headache Center shares her experience as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]

Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.

Bradley Torphy, MD, and Julio R. Vieira, MD, share unmet needs and clinical pearls for the management of migraine.

Experts in headache medicine review novel therapeutic agents under investigation and the evolving treatment landscape for migraine.

Julio R. Vieira, MD, leads a discussion on the importance of follow-up visits for patients with migraine and considerations for switching therapies.

Andrew C. Charles, MD; Bradley Torphy, MD; and Jessica Ailani, MD, review current FDA approved CGRP monoclonal antibodies available for the preventive treatment of migraine.

Experts in headache medicine discuss the role of CGRP-based therapy for migraine prevention.

Drs Bradley Torphy and Jessica Ailani share thoughts on using consensus statements to guide the treatment of migraine.

Sait Ashina, MD, reviews current AHS (American Headache Society) treatment recommendations for the acute and preventive treatment of migraine.

Dr Julio R. Vieira defines acute versus preventive treatment for migraine and highlights the differences in goals of therapy for each.

Sait Ashina, MD, and Jessica Ailani, MD, comment on the importance of individualized treatment regimens for the management of migraine.

Experts in neurology, Drs Julio R. Vieira, Jessica Ailani, and Bradley Torphy review diagnostic tools available for migraine, including patient use of headache diaries.

Jessica Ailani, MD, and Bradley Torphy, MD, discern the signs of migraine and comment on the importance of ensuring accurate diagnosis for patients.

Drs Bradley Torphy and Julio R. Vieira share insight on approaching the diagnosis of migraine as well as current challenges in diagnosis.

Andrew C. Charles, MD; Jessica Ailani, MD; and Sait Ashina, MD, discuss the impact of migraine on a patient’s quality of life and share strategies for reducing the clinical burden of disease.

Andrew C. Charles, MD, and Sait Ashina, MD, provide an overview of the pathophysiology of migraine and discuss its 5 clinical phases.

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.

A discussion on when a patient should be referred to a headache specialist for preventive migraine treatment.

Jessica Ailani, MD, details how the phase 3 ADVANCE trial will shape the research of future agents for preventive migraine treatment.

A key opinion leader discusses the use of oral agents for the preventive treatment of migraine.

Dr Christopher Gottschalk shares how the clinical trial data for CGRP monoclonal antibodies affect patient selection for preventive migraine treatment.

A panel of neurologists review clinical trial data on several CGRP monoclonal antibodies for migraine preventive treatment.

Expert neurologists discuss the use of CGRP monoclonal antibodies to prevent migraines.

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, provides an overview of the use of onabotulinumtoxinA as a preventive migraine treatment.